ERBB2 and neoplasm: The objective of this study was to evaluate the efficacy, the modifications to the TME immune profile, and the long-term immunotherapeutic effects induced by the HER2-retargeted R-337 in the immunologically hot CT26 tumor and to obtain an insight on how R-337 induces the antitumor immune response.